Ra Pharmaceuticals Inc

What indicators would you like to setup a trade for?

Candlestick Daily volume index Bar reversal Edit

Trade setup

Position Order Entry Exit Stop Loss Risk Return Expectancy
Long 10 4.5 20% 25% 1.6% -0.8% -3.4%
Short 5 4.2 40% 67% 1.9% -3.2% -5.9%

What indicators would you like to backtest?

Candlestick Daily volume index Bar reversal Edit

Backtest results

Position Trades Duration Win rate Win/loss Avg win Avg loss Return
Long 10 4.5 20% 25% 1.6% -0.8% -3.4%
Short 5 4.2 40% 67% 1.9% -3.2% -5.9%

Company

Indicator

Code Company Date Close Change Indicator Value Signal

Trading Performance

Woodie Pivot Point

Score

-1.45

Position Trades Duration Win Rate Win/Loss Avg Win Avg Loss Return
LONG 128 3.9 0.40% 0.64% 4.1% -2.9% -20.4%
SHORT 126 3.8 0.37% 0.57% 2.9% -3.8% -180.4%

Summary

Technical Analysis

Ra Pharmaceuticals Inc (RARX)


Indicator:

WOODIE PIVOT POINT


Signal Strength: MEDIUM
Recommendation:

Indicator can be used in isolation or in additional to another technical indicator to confirmation for trading position.


Ra Pharmaceuticals Inc (NASDAQ:RARX) current pivot point (Woodie) is:
$46.55.

The current resistance levels are:
(R1) $46.85
(R2) $47.09

The current support levels are:
(S1) $46.31
(S2) $46.01



One of the key differences in calculating Woodies Pivot Point to other pivot points is that the current sessions open price is used in the PP formula with the previous sessions high and low.

Calculation: Woodie Pivot Point:
1) R2 = PP + High – Low;
2) R1 = (2 X PP) – Low;
3) PP = (H + L + 2C) / 4;
4) S1 = (2 X PP) – High;
5) S2 = PP – High + Low – Closing Price – High – Low;


PROFILE: Ra Pharmaceuticals Inc (RARX)


Stock Exchange: NASDAQ
Company: Ra Pharmaceuticals Inc
Ticker Codes: | RARX | NASDAQ:RARX |

About Ra Pharmaceuticals Inc (NASDAQ:RARX):

Ra Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system in the United States. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules. Its lead product candidate is RA101495, an injection into the tissue under the skin that has completed Phase II clinical trial for the treatment of paroxysmal nocturnal hemoglobinuria (PNH); and is in Phase II clinical trial for treating patients with generalized myasthenia gravis (gMG), as well as in Phase 1b clinical trial for treating atypical hemolytic uremic syndrome (aHUS) and lupus nephritis (LN). The company's preclinical testing products include Factor D inhibition for orphan renal and dense deposit diseases, and C3 glomerulonephritis; Oral C5 inhibitor for PNH, gMG, aHUS, LN, and central nervous system (CNS) diseases; and other complement inhibitors for autoimmune/CNS diseases. It has multi-target collaboration and license agreement with Merck & Co., Inc. Ra Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Cambridge, Massachusetts.

Top 10:

Woodie Pivot Point

Download
Company Close Change(%) Volume Value Signal
INO Inovio Pharma 4.36 9.3 34,675,337 -0.01 BEARISH
ORBC Orbcomm 3.44 4.2 2,627,367 -0.19 BEARISH
HSII Heidrick & Struggles 22.2 3.8 207,252 -0.4 BEARISH
FOSL Fossil Group 4.28 2.6 1,864,683 -0.04 BEARISH
EZPW Ezcorp Inc 4.79 2.4 1,002,907 0 BEARISH
NH Nanthealth 1.8 1.7 455,155 -0.1 BEARISH
DXCM Dexcom 281.48 1.2 1,087,228 -0.16 BEARISH
CETV Central European Media 4.4 0.9 2,014,369 -0.02 BEARISH
ELGX Endologix Inc 1.45 0.7 546,513 -0.02 BEARISH
CSWI CSW Industrials 70.37 0.4 93,298 -0.55 BEARISH